Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
The stock still presents a compelling case for investors, provided the clinical trial data can back up the early promise in its lead drug candidate.
Viking Therapeutics' stock has plummeted 66% from its peak, with a recent 8.4% decline in 2026. Despite the setback, the company holds promising drug candidates, notably VK2735, a dual GLP-1 and GIP agonist in development for obesity and type 2 diabetes. This novel approach offers potential advantages over existing treatments like Eli Lilly's Zepbound/Mounjaro, Foundayo, and Novo Nordisk's Ozempic/Wegovy, positioning VKTX for a possible stock rerating.
Brief written by urgent.news from Motley Fool's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
